CG Oncology, Inc. Stock Split Ratio
CG Oncology, Inc. (CGON) reported Stock Split Ratio of 10.50% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-02-27
- CG Oncology, Inc. stockholders' equity note, stock split, conversion ratio for the quarter ending 2025-03-31 was 10.50%, a 0.00% change year-over-year.
- CG Oncology, Inc. stockholders' equity note, stock split, conversion ratio for the quarter ending 2024-03-31 was 10.50%.
- CG Oncology, Inc. stockholders' equity note, stock split, conversion ratio for fiscal 2025 was 10.50%, a 0.00% change from fiscal 2024.
- CG Oncology, Inc. stockholders' equity note, stock split, conversion ratio for fiscal 2024 was 10.50%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 3 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 6 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 9 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|---|---|
| 2025-12-31 | 10.50% 10-K · filed 2026-02-27 | |||
| 2025-09-30 | 10.50% 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | 10.50% 10-Q · filed 2025-08-08 | |||
| 2025-03-31 | 10.50% 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | 10.50% 10-K · filed 2025-03-28 | |||
| 2024-09-30 | 10.50% 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | 10.50% 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | 10.50% 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |